---
title: Identification and Isolation of CAR-T Cells with Enhanced Therapeutic Efficacy
description: Discover how VisionSort identifies distinct CAR-T cell subsets, enhancing therapeutic efficacy and clinical responses in cancer treatment by targeting metabolically unique cells.
---

[Skip to content](https://info.thinkcyte.com/identification-and-isolation-of-car-t-cells-with-enhanced-therapeutic-efficacy#main-content)

[![THINKCYTE-LOGO-DK-1000W](https://info.thinkcyte.com/hs-fs/hubfs/BRAND-ASSETS/THINKCYTE-LOGO-DK-1000W.png?width=225&height=41&name=THINKCYTE-LOGO-DK-1000W.png)](https://thinkcyte.com/)

Open main navigation

Close main navigation

- [Contact us](https://info.thinkcyte.com/contact-thinkcyte)

[Contact us](https://info.thinkcyte.com/contact-thinkcyte?hsLang=en)

**Isolation of CAR-T Cells with Enhanced Therapeutic Efficacy**

![Identification and Isolation of CAR-T Cells with Enhanced Therapeutic Efficacy](https://info.thinkcyte.com/hubfs/Assets/Screenshot%202025-01-17%20113402.jpg "Identification and Isolation of CAR-T Cells with Enhanced Therapeutic Efficacy")

Introduction:

Chimeric antigen receptor T-cells (CAR-T) have emerged as promising new approach for the treatment of cancer, with over 500 CAR-T worldwide clinical trials underway in 2021. Conventional thinking was that all CAR-T cells have similar therapeutic potential, however new research has found that not all CAR-T cells are created equal. A recent study showed that CAR-T cells with lower levels of glycolysis led to better clinical responses in leukemia patients. Here we use VisionSort to identify metabolically distinct CAR-T cell subsets without the use of molecular labels or tags as an approach to identify cells with the potential for higher therapeutic efficacy. 

Summary:

1. VisionSort can identify and classify metabolically distinct subsets of CAR-T cells without external markers or tags
2. A label-free approach can significantly contribute to identifying and isolating higher quality CAR-T therapy products
3. This could potentially improve CAR-T cell therapy efficacy and clinical outcomes.

Register to find out more.

Copyright © 2026, ThinkCyte Inc.